Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.80M.
Undervalued
The company’s latest PE is -13.48, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 115.97M shares, increasing 5.67% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 7.98M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.92.